Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomised trials (Lancet Oncology, 2022)

(untitled) - Early Breast Cancer Trialists' Collaborative Group (EBCTCG)